Agoracom Blog Home

Posts Tagged ‘small cap stocks’

VIDEO – Molecule $MLCL.ca Is At The Forefront of The Cannabis Beverage Revolution, with Landmark Licensing Deal And Estimated Revenue Run Rate of $23.2m $WEED.ca $TPX.A.ca $ACB.ca

Posted by AGORACOM-JC at 9:30 AM on Thursday, January 28th, 2021

Phil Waddington / President and CEO of Molecule Holdings Inc. / (MLCL:CSE) discusses the craft-focused, cannabis beverage production company’s cutting-edge work in the nascent Canadian market. 

Boasting a 200,000 square foot production facility based in Ontario, the company has just been given the green light to begin selling its unique line of cannabis-infused beverages throughout Canada, starting in Ontario and Québec. 

The company’s recent partnership with Vortex Cannabis Inc. allows Molecule to bring its unique line of cannabis-infused beverage products to market this year, while completing its own sales amendment application. 

Molecule Highlights:

  • Molecule’s recent deal with Vortex Cannabis Inc. allows it to begin selling its unique line of cannabis-infused beverages throughout Canada this year.
  • Vortex will sell products produced by Molecule to provincial retailers, starting with Ontario and Québec.
  • Molecule has a 200,000 square foot production facility based in Ontario, offering huge capacity.
  • The company forecasts 2021 Q1 revenue of $3.5m, 2021 Q2 revenue of $5.8m, and a 2021 Run Rate revenue of $23.2m
  • An early leap of faith into this emerging industry in 2018 has positioned the company well ahead of the pack now.
  • “We are excited to move into full scale production and sale,” says CEO Phil Waddington.

Novamind $NM.ca Reaches Major Milestones for #Ketamine and #Spravato(TM) Treatments $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:15 AM on Thursday, January 28th, 2021

  • Announced significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments.
  • Clients receiving ketamine treatment at Novamind’s Cedar Psychiatry clinics are offered specialized therapy, pre- and post-ketamine-administration (ketamine-assisted psychotherapy).
  • Cedar Psychiatry specializes in evidence-based therapeutic protocols that facilitate the integration of ketamine experiences and optimize treatment outcomes for clients.

TORONTO, ON / January 28, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is proud to announce significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments.

Launched in 2016, Cedar Psychiatry is a leading provider of innovative, evidence-based mental health therapies in the United States.

Clients receiving ketamine treatment at Novamind’s Cedar Psychiatry clinics are offered specialized therapy, pre- and post-ketamine-administration (ketamine-assisted psychotherapy). Cedar Psychiatry specializes in evidence-based therapeutic protocols that facilitate the integration of ketamine experiences and optimize treatment outcomes for clients.

The number of ketamine treatments administered at Cedar Psychiatry clinics grew 90% from 2019 to 2020. During the same period, total Spravato™ treatments at Cedar Psychiatry clinics have grown over 400%. Spravato™ is a version of ketamine that was approved by the U.S. FDA for treatment-resistant depression (TRD) in March 2019, and for major depressive disorder (MDD) with suicidal ideation or behaviour in August 2020. Clinical research studies that supported FDA approval showed that Spravato™ can effectively benefit people with these conditions, which can be difficult to treat.

“Spravato™ requires specialized infrastructure and processes that can be difficult for small mental health practices to implement, but Cedar Psychiatry has the scale and expertise to effectively manage the challenges of offering these novel medications to our clients,” commented Dr. Reid Robison, Chief Medical Officer and Director of Novamind.

“The need for innovative mental health services has never been greater. This demand is reflected in a sharp increase in visits to our clinics, and the growing adoption by our clients of alternative mental health treatments” added Yaron Conforti, CEO and Director of Novamind.

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/754111-novamind-reaches-major-milestones-for-ketamine-and-spravato-tm-treatments/messages/2300736#message

ImagineAR $IP.ca $IPNFF and Interactive Marketing Promotions to Deliver Augmented Reality Engagements to US Automobile Event Marketplace $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:47 AM on Thursday, January 28th, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Three-year $150,000 SDK licensing and revenue sharing agreement executed.

  • Announced the execution of a three-year $150,000 SDK licensing plus revenue sharing agreement to deliver Augmented Reality (“AR”) immersive experiences integrated with the new IMP Event App ( www.touchaprize.com ).  
  • In 2019, IMP successfully delivered an AR Scavenger Hunt for the Greater Milwaukee Auto Show presented by Adamm. IMP recent Auto Show clients include: Greater Milwaukee , Alabama , St. Louis , Hawaii International, Sacramento , Orlando , Tampa and other Motor Trend shows.

VANCOUVER, BC and ERIE, Pa, Jan. 28, 2021 – Imagine AR Inc. (CSE:IP) (OTCQB: IPNFF) (“ImagineAR”) and Interactive Marketing Promotions  (“IMP) , are excited to announce the execution of a three-year $150,000 SDK licensing plus revenue sharing agreement to deliver Augmented Reality (“AR”) immersive experiences integrated with the new IMP Event App ( www.touchaprize.com ).  In 2019, IMP successfully delivered an AR Scavenger Hunt for the Greater Milwaukee Auto Show presented by Adamm. IMP recent Auto Show clients include: Greater Milwaukee , Alabama , St. Louis , Hawaii International, Sacramento , Orlando , Tampa and other Motor Trend shows.

Using ImagineAR’s licensed AR SDK and cloud-based studio suite, IMP will be delivering immersive AR engagements for manufacturers to consumers attending online virtual and near future in-person automobile shows throughout North America.  In addition to on-site and virtual AR Scavenger Hunts, AR will be used to place leading product experts from automobile manufacturers virtually ‘on location’ with the consumer to provide new model information as either an avatar or hologram.

“ImagineAR continues to be the global leader in delivering dynamic mobile augmented reality engagements.  By integrating the ImagineAR platform with our IMP app, we are providing automobile shows the most advanced interactive consumer attendee engagement solution and data capture tool,” said Bob Kames, CEO IMP .

Read More: https://agoracom.com/ir/Imaginear/forums/discussion/topics/754103-imaginear-and-interactive-marketing-promotions-to-deliver-augmented-reality-engagements-to-us-automobile-event-marketplace/messages/2300725#message

VIDEO – New Age Metals Has 2.9Moz of #Palladium Equivalent (M&I), 7 #Lithium Projects And Eric #Sprott As An Investor To Win The Green Metal Revolution $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 4:33 PM on Wednesday, January 27th, 2021

Harry Barr / Chairman, CEO & Director of New Age Metals Inc. / (TSXV:NAM); (OTC:NMTLF); (FSE:P7J) discusses the River Valley PGM deposit, as well as their Lithium holdings.  Advancement of the River Valley PGM deposit is ongoing studies conducted continue to solidify the value of the 2.9Moz Palladium Equivalent (Measured & Indicated) resource.

With Palladium increasing 25%, the $2300 threshold for Palladium has been breached, and investors are starting to take notice; as they should.  One of mining’s great investors, Eric Sprott is already a strategic shareholder. 

River Valley Highlights 

  • 100% ownership of a multi-million-ounce district scale North American Palladium asset
  • 100 km north east of Sudbury, $40M of expenditures at River Valley Palladium Project
  • Positive Preliminary Economic Assessment (PEA)complete, working towards Prefeasibility (PFS)
  • Excellent exploration upside across the Company’s project portfolio
  • River Valley Project payable metal suite hosts other battery metals  including copper, nickel, cobalt

Have a seat and find out why New Age Metals is a leader of Green Metal Projects in North America.

POET Technologies $PTK.ca $POETF Announces Upsize to Private Placement

Posted by AGORACOM-JC at 10:31 AM on Wednesday, January 27th, 2021
  • Agreed to increase the size of the Placement.
  • The Company will now issue up to 14,706,000 units from the treasury of the Company, at a price of $0.85 per Unit for total gross proceeds of up to approximately $12.5 million (the “ Placement ”).

TORONTO, Jan. 27, 2021 — POET Technologies Inc. (“ POET ” or the “ Company ”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, is pleased to announce that in connection with the private placement (the “ Placement ”) announced by the Company earlier today, the Company and a syndicate of agents led by Cormark Securities Inc., and including IBK Capital Corp. and PI Financial Corp. (collectively, the “ Agents ”), have agreed to increase the size of the Placement. The Company will now issue up to 14,706,000 units (the “ Units ”) from the treasury of the Company, at a price of $0.85 per Unit (the “ Issue Price ”) for total gross proceeds of up to approximately $12.5 million (the “ Placement ”).

In addition, the Company and the Agents have also agreed that the Agents shall have an option (the “ Agents’ Option ”) to purchase up to an additional 2,941,200 Units on the same terms, exercisable up until the time of closing of the Placement, for market stabilization purposes and to cover over-allotments, if any. If the Agents’ Option is exercised in full, an additional approximately $2.5 million will be raised and the aggregate proceeds of the Placement will be up to approximately $15.0 million.

In connection with the Placement, the Company will pay a cash commission to the Agents equal to 6.0% of the aggregate gross proceeds of the Placement and will issue broker warrants equal to 6.0% of the number of Units sold under the Placement, each exercisable to acquire one Common Share at the Issue Price for a period of 24 months from the closing date of the Placement.

Read More: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/754040-poet-technologies-announces-upsize-to-private-placement/messages/2300523#message

VIDEO – Universal #PropTech $UPI.ca Has Generated $35,000,000+ In Revenues Over Past 3 Years Delivering Healthy Building Solutions, Now Prepares To Deliver #COVID-19 Solutions To Tier-1 Clients Across Canada #AI #IoT $SNE $MSFT $HON

Posted by AGORACOM-JC at 4:16 PM on Tuesday, January 26th, 2021

As the name implies “PropTech” is a combination of two words and stands for “property technology.”  As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing PropTech industry, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada. 

More than just lip service, UPI clients include:

  • Federal Government facilities for over 40 years
  • Manulife
  • Brookfield
  • Billy Bishop Airport
  • University of Toronto
  • …. and many more

Now UPI is preparing to service those clients and take another big step forward with this announcement on January 25, 2021 – Universal PropTech Announces Signing of Canadian Distribution Agreement with Fresh-Aire UV to Help Combat SARS-CoV-2 in Schools, Colleges, Universities, Government Facilities and Seniors’ Homes.  What it means can best be summarized in the following quote by Chris Hazelton, President & CEO of UPI:

“Our clients expect us to have the right Covid-19-fighting solutions that meet the needs of their uniquely designed facilities.  Fresh-Aire UV solutions allow us to deliver a highly integrated HVAC package to fit those schools, colleges, universities, government facilities and seniors’ homes, immediately, and enable us to remain our customer’s trusted advisor in healthy buildings.”  

Watch our interview with CEO Hazelton to learn about the Company’s established PropTech success, COVID-19 solution for Canadian buildings and where the Company is going.

POET Technologies $PTK.ca $POETF Announces Brokered Private Placement of Units

Posted by AGORACOM-JC at 8:35 AM on Tuesday, January 26th, 2021
  • Announced a brokered private placement led by Cormark Securities Inc. of up to 11.8 million units at a price of $0.85 per Unit, to raise gross proceeds of up to $10.0 million .
  • Marc Lustig , founder and former Chairman of Origin House has committed to be a lead participant in the Placement.

TORONTO , Jan. 26, 2021 – POET Technologies Inc. (” POET ” or the ” Company “) (TSX Venture: PTK) (OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, is pleased to announce a brokered private placement (the ” Placement “) led by Cormark Securities Inc. (” Cormark “) of up to 11.8 million units (the ” Units “) at a price of $0.85 per Unit, to raise gross proceeds of up to $10.0 million . Marc Lustig , founder and former Chairman of Origin House has committed to be a lead participant in the Placement.

Suresh Venkatesan , Chairman and CEO of POET Technologies commented: “We are extremely pleased to see this investment led by Marc Lustig , a well-known Canadian entrepreneur and investor. We are happy to have Marc as a supporter at this point in POET’s growth plan and the proceeds of this offering will strengthen the Company’s balance sheet while streamlining the Company’s plans to seek an additional listing for its Common Shares on NASDAQ Capital Market.”

Each Unit will consist of one common share of the Company (a ” Common Share(s) “) and one Common Share purchase warrant (a ” Warrant “). Each Warrant will entitle the holder to purchase one additional Common Share at a price of $1.15 per Common Share for a period of 24 months following the closing of the Placement. The Warrants are subject to an accelerated expiry if, following the date that is four months and one day after the date of issuance of the Units and prior to the expiry date of the Warrants, the daily volume weighted average trading price of the Shares exceeds $2.30 for ten consecutive trading days. The Placement price of $0.85 per Unit represents a discount of 5.5% of the VWAP (volume weighted average price) of POET’s Common Shares on the TSX Venture Exchange (” TSXV “) for the 5 trading days ended January 25, 2021 .

Closing of the Placement is subject to receipt of all necessary corporate and regulatory approvals, including the approval of the TSXV. Closing of the Placement is anticipated to occur on or about February 11, 2021.

Read More: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/753933-poet-technologies-announces-brokered-private-placement-of-units/messages/2300228#message

Novamind $NM.ca Announces Marketing Services Agreements $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:29 AM on Tuesday, January 26th, 2021
  • Entered into marketing services agreements with Octagon Media Corp.
  • AGORA Internet Relations Corp
  • And a consulting agreement with Venture North Capital Inc.

TORONTO, ON / January 26, 2021 / Novamind Inc., (CSE:NM) (“Novamind” or the “Company”) a mental health company specialized in psychedelic medicine, announces that is has entered into marketing services agreements with Octagon Media Corp. (“Octagon”) (the “Octagon Marketing Agreement”), AGORA Internet Relations Corp (“AGORA”) (the “AGORA Marketing Agreement”), and a consulting agreement with Venture North Capital Inc. (“VNC”) (the “VNC Agreement”).

In connection with the services provided by Octagon under the Octagon Marketing Agreement, the Company will pay Octagon a cash fee of US$123,000 upon signing, as well as grant Octagon a 12-month option to purchase 100,000 common shares in the capital of the company (the “Shares”) at a price of CAN$1.65 per Share, which will vest fully at signing, and 400,000 warrants to purchase Shares at a price of CAN$1.65 per Share for a period of twelve months from the date of issuance.

The Company also announces that it has entered into a 12-month online marketing services agreement with AGORA Internet Relations Corp., to carry out an online marketing campaign for the purposes of targeting new potential investors that would be specifically interested in the Company’s business model, as well as engaging current shareholders.

In connection with the services provided by AGORA under the AGORA Marketing Agreement, the Company will pay AGORA aggregate consideration of CAN$75,000 plus applicable taxes. The consideration is to be paid via the issuance of Shares. CAN$15,000 of Shares are payable upon commencement of the AGORA Marketing Agreement on January 15, 2021, in consideration of the setup and creation of tools to be used in connection with the services, and an additional CAN$15,000 of Shares are payable every three months thereafter until the end of the AGORA Marketing Agreement’s term.

The number and deemed price of the Shares to be issued will be determined after the date services are provided in each period and are to be calculated using the closing price of the Shares on the Canadian Securities Exchange on each date on which shares are to be issued.

The Company also announces that it has entered into a consulting agreement with Venture North Capital Inc., pursuant to which VNC will provide the Company with investor relations, marketing and communications services for a 6-month term.

In connection with the services provided by VNC under the VNC Agreement, the Company agreed to pay VNC a monthly cash payment of CAN$7,500 per month for six months. The Company has also agreed to issue VNC warrants to purchase 100,000 Shares at a price of CAN$1.65 per Share for a period of twelve months from the date of issuance.

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.

Contact Information

Novamind

Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Bill Mitoulas, Investor Relations
Email: [email protected]

Forward-Looking Statements

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

None of the securities discussed in this news released have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued are anticipated to be issued in reliance upon available exemptions from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

SOURCE: Novamind Inc.

AI/ML’s $AIML.ca $FIRZF Health Gauge announces successful Proof of Concept deployment and findings for study funded by The Bill and Melinda Gates Foundation $ADK.ca $PFM.ca $DM.ca

Posted by AGORACOM-JC at 8:09 AM on Tuesday, January 26th, 2021
  • Subsidiary, Health Gauge, successfully displayed its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation, further validating its technology.
  • Health Gauge was invited in 2019 to participate, as the sole technology provider, in a Bill and Melinda Gates Foundation funded initiative with ICDDR , B (the International Centre for Diarrhoeal Disease Research of Bangladesh) on a research project to study ways to reduce pregnancy complications and mortality, by making healthcare more accessible using wearable solutions.

January 20, 2021 – AI/ML Innovations Inc. (CNSX :AIML.CN ) (OTC:FIRZF) , a company focused on acquiring and furthering Artificial Intelligence/Machine Learning technologies that address urgent societal needs, announces that its subsidiary, Health Gauge, successfully displayed its proof-of-concept deployment in a study funded by The Bill and Melinda Gates Foundation, further validating its technology. Health Gauge was invited in 2019 to participate, as the sole technology provider, in a Bill and Melinda Gates Foundation funded initiative with ICDDR , B (the International Centre for Diarrhoeal Disease Research of Bangladesh) on a research project to study ways to reduce pregnancy complications and mortality, by making healthcare more accessible using wearable solutions. Health Gauge was invited to participate in this study as a result of ICDDR,B’s learning of Health Gauge’s break-through solution in digital pulse and ECG analysis, using simple, affordable, and quality digital signal capture.  For this study, Health Gauge’s personal health monitoring solution, including its wearable device, smart phone app, and AI-driven cloud processing platform was used, in conjunction with the support of community-based health service providers.

Conclusion

Studies such as this validate the proof-of-concept of Health Gauge’s products, and show the vast and varied commercial opportunities available within Health Gauge’s bespoke business model. It speaks to the merits and importance of how Health Gauge’s latest generation solutions can help solve important community health problems, in affordable ways, while readily fitting into existing managed care programs – anywhere. Physicians, other healthcare professionals, and individuals can apply and adapt the Health Gauge solution to a number of different health conditions and settings for personal health monitoring and management – showing the larger value of Health Gauge’s device and applications.

Blood pressure related pregnancy maladies are of concern globally, and a leading cause of death amongst pregnant women. Health Gauge’s products have both the ability and opportunity to capitalize on this critical women’s health issue, while providing an invaluable service that has a direct impact on health outcomes.

Background

The study, which commenced in 2019, focused on serving pregnant women who were at risk of developing eclampsia, a hypertension-related significant health risk. Hypertensive disorders of pregnancy (HDP) are extremely dangerous to both the mother and child, and are in fact one of the three leading causes of maternal death worldwide. While hypertension complicates 10% of all pregnancies and is responsible for 14% for all maternal deaths globally, in the developing world it is of even greater concern where mortality rates can be as high as 20%.

Read More: https://agoracom.com/ir/AIMLInnovations/forums/discussion/topics/753924-ai-ml-s-health-gauge-announces-successful-proof-of-concept-deployment-and-findings-for-study-funded-by-the-bill-and-melinda-gates-foundation/messages/2300216#message

Novamind $NM.ca to Present at Inaugural KCSA Psychedelics Investor Conference $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:31 AM on Monday, January 25th, 2021
  • The two-day event will feature presentations by eminent psychedelics companies and industry leaders
  • Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST

TORONTO, ON / January 25, 2021 / Novamind Inc. (CSE:NM) (“Novamind” or the “Company”), a mental health company specialized in psychedelic medicine, today announced the Company’s participation at the Psychedelics Investor Conference, hosted by KCSA Strategic Communications on Tuesday, January 26th and Wednesday, January 27th from 9:00 AM – 12:30 PM EST.

The two-day event will feature presentations by eminent psychedelics companies and industry leaders. Novamind CEO and Director Yaron Conforti will present on Wednesday, January 27th at 9:55 AM EST.

“We look forward to connecting with industry leaders and investors to discuss Novamind’s operating model for clinical care and clinical research in psychedelic medicine,” said Conforti.

Read more: https://agoracom.com/ir/Novamind/forums/discussion/topics/753850-novamind-to-present-at-inaugural-kcsa-psychedelics-investor-conference/messages/2300029#message